Conclusion. Iceland is on track to eliminate HCV, but challenges such as increasing drug use in the community and homelessness need to continuously monitored and addressed; they may jeopardize the success of elimination efforts.

Disclosures. All Authors: No reported Disclosures.

2896. Reduction in Liver-related Mortality Among HCV Infected Persons Is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort
Aded A. Butt, MD, MS1; Peng Yan, MS2; Samia Aslam, BS3; Vincent Lo Re III, MD MSCE4 and Obaid Shaikh, MD5; 1Well Cornell Medical College, Doha, Ad Dawhah, Qatar; 2VAPHS, Pittsburgh, Pennsylvania; 3VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania; 4University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Session: 310. Hepatitis C: Progress on Elimination and Treatment Saturday, October 5, 2019: 3:27 PM
Background. Beneficial effect of hepatitis C virus (HCV) treatment with directly acting antiviral agents (DAAs) upon overall mortality is well-established. However, the effect of treatment upon liver-related mortality is not well documented.

Methods. We used ERCHIVES database to identify all chronic HCV-infected persons between January 1, 2002 and December 31, 2016. We excluded those with HIV or HBV co-infection or hepatocellular carcinoma. HCV treatment status was defined as prescription of pegylated interferon (PEG)/ribavirin (RBV) for >24 weeks, PEG/RBV plus boceprevir or telaprevir, or a newer DAA regimen for >8 weeks. Propensity score-matched untreated controls were identified for each treated person. We linked HCV+ cases to the National Death Index (NDI) data updated to the end of 2016. Cause of death was retrieved from the underlying cause listed on the death certificate by using ICD-10 codes. The listed primary cause was assigned as the cause of death. Each cause of death was categorized as “Liver related” or “Not liver related” by two physician members of the study team. Liver-related causes included viral hepatitis-related causes, complications of liver disease, and hepatocellular carcinoma, but excluded any cause where alcohol or any other known liver disease other than viral hepatitis was specified.

Results. Among 34,412 treated and 21,287 untreated controls, there were 13,096 deaths, of which 2,474 (18.9%) were liver related. Overall liver-related mortality rate per 100 person-years of follow-up was 0.64 in the treated and 1.24 in the untreated group (P). Among the treated group, the liver-related mortality rate per 100 person-years was 0.14 for those who achieved SVR and 1.26 among those who did not achieve SVR. When stratified by treatment regimen, those treated with PEG/RBV had a mortality rate of 0.73 vs. 0.24 for those treated with a DAA regimen. However, further stratification by attainment of SVR revealed that the difference between regimens was almost entirely driven by the difference in SVR rates (see table).

Conclusion. HCV-infected persons who receive treatment have a substantial reduction in liver-related mortality. This reduction is largely driven by attainment of SVR and is independent of the regimen use when stratified by SVR attainment.

Table. Liver related mortality rate per 100 person-years of follow up.

|               | Number of deaths | Rate/100 person-years | P-value* |
|---------------|------------------|-----------------------|----------|
| **Overall**   |                  |                       |          |
| Group A: HCV treated | 825     | 0.64                  | --       |
| Group B: HCV untreated | 1649    | 1.24                  | <.0001   |
| **Among those treated by treatment response** |          |                       |          |
| SVR achieved | 111              | 0.14                  | --       |
| SVR not achieved | 714       | 1.25                  | <.0001   |
| **By treatment regimen** |          |                       |          |
| PEG/RBV | 725 | 0.72 | -- |
| PEG/GRBV, SVR achieved | 68 | 0.13 | <.0001 |
| PEG/GRBV, SVR not achieved | 667 | 1.3 | <.0001 |
| DAA SVR achieved | 40 | 0.14 | 0.01 |
| DAA SVR not achieved | 32 | 0.53 | <.0001 |

Disclosures. All Authors: No reported Disclosures.

2897. Collocated Buprenorphine Is Associated with Improved HCV Visit Completion Among Patients in Who Inject Drugs (PWID): Data From theANCHOR Study
Elana S. Rosenthal, MD1; Rachel Silk, RN, BSN, MPH1; Poonam Mathur, MD, MPH2; Rahwa Eysay, MSN, FNP3; Laura Nußdorf, BA1; Kristi Hill, BA1; Aaron D’Amico, BS4; Christopher Brokus, BS5; Phylla Bijole, BA, MA5; Miriam Jones, N/A5; Randy Kier, N/A5; David Sternberg, BA1; Henry Masur, MD5; Shyam Kottill, MD, PhD5 and Sarah Kattakuzhy, MD5; 1University of Maryland School of Medicine, Institute of Human Virology, Washington, DC; 2DC Partnership for HIV/AIDS Progress, Washington, DC; 3University of Maryland School of Medicine; 4DC Partnership for HIV/AIDS Progress, Washington, DC; 5National Institutes of Health; DC Partnership for HIV/AIDS Progress, Bethesda, Maryland; 6Harvard Medical School, Boston, Massachusetts; 7National Institutes of Health, DC Partnership for HIV/AIDS Progress, Bethesda, Maryland; 8HIPS, Washington, DC; 9University of Maryland School of Medicine, DC Partnership for HIV/AIDS Progress, Baltimore, Maryland
Session: 310. Hepatitis C: Progress on Elimination and Treatment Saturday, October 5, 2019: 3:39 PM
Background. Engaging PWID in HCV treatment and monitoring for reinfection is critical to eliminate HCV and improve health in people who use drugs. However, PWID are often marginalized and can be difficult to engage and retain in care. The collocation of HCV treatment with buprenorphine to treat opioid use disorder (OUD) may improve visit adherence in this population.

Methods. ANCHOR is a single site study evaluating treatment of HCV in PWID with chronic HCV, OUD, and IDU. Participants receive sofosbuvir/velpatasvir x12 weeks and are offered collocated buprenorphine. HCV visits occur at weeks 4, 12, 24, 48, 72 and 96.

Results. At screening, the 100 enrolled patients were predominantly male (76%), black (93%), middle-aged (median 57years), injected opioids daily or more (58%), and were not on OAT (67%). Fifty-five (55%) patients were initiated on collocated buprenorphine at some point after day 0. Being on collocated buprenorphine at the time of HCV visit was associated with increased likelihood of visit attendance at weeks 12 (P = 0.002), 24 (P = 0.01), 48 (P = 0.02), 72 (P = 0.003), and 96 (P = 0.04). For patients who attended study visits, being on collocated buprenorphine was associated with a shorter time between planned visit and actual visit at weeks 12 (P = 0.03), 24 (P = 0.04), 48, 72 and 96.

Conclusion. Evidence-based treatment of HCV and OUD are critical to improving health in PWID. The collocation of HCV treatment with office-based buprenorphine may improve adherence to visits and visit timing, especially in long-term follow-up. Infectious disease providers should offer collocated buprenorphine as a tool to improve long-term outcomes and engagement in this high-risk population.

Disclosures. All Authors: No reported Disclosures.

2898. Achieving Hepatitis C SVR12 of 95% in Mono-Infected Patients with Severe Comorbidities Using Volunteer Staff and Minimal Clinic Visits and Phlebotomy
Charles M. van der Horst, MD1; Gary Greenberg, MD2; Erin Kirchgessner, MSW2; Amanda Vaughan, PharmD3; Edie Alfano-Sobsey, PhD4; Amy Riggelman, BS5; Ayat Soufan, MSW6; Mandy Horner, RN, BN1; Asha Nadabar, BS1; Diana Castillo, BA1; Elizabeth Campbell, MD7 and Sue Lynn Ledford, DrPH1; 1Open Door Clinic of Urban Ministries of Wake County, Chapel Hill, North Carolina; 2Wake County Public Health Department, Raleigh, North Carolina; 3Wellcare, Raleigh, North Carolina
Session: 310. Hepatitis C: Progress on Elimination and Treatment Saturday, October 5, 2019: 3:51 PM
Background. HCV is the most common chronic bloodborne infection in the United States with an estimated 3.5 million infected. With direct-acting antivirals, cure can be achieved in 8 to 12 weeks. To achieve WHO elimination targets by 2030 (>90% reduction in transmission) health systems require improved case detection, access to care, and simplified treatment protocols that patients, challenged by substance use and mental health disorders, can readily complete.

Methods. In 2016, Wake County, NC began HCV testing at 32 sites finding prevalence of 5 shelters and 15 clinic visits in the county. A program of simplified HCV treatment protocol, used in the high prevalence settings of Ukraine and Burma, was implemented at the Open Door Clinic – a free clinic for uninsured persons living in poverty in Wake County. After initially using genotype-specific therapy, we switched to pegyalted interferon (PEG)/ribavirin (RBV) for 12 weeks. Clinic visits were limited to pre-treatment and 12 weeks after treatment completion. Patients were contacted weekly via text to check on their health and adherence.

Results. Thirty HCV mono-infected patients have initiated treatment including 9 women. 21 were infected by IDU, 5 by transfusion, 3 by sex with an infected partner, and 5 have unknown risk. In genotype (GT) testing 22 have GT1, 3 GT2, & 4 GT3. Major comorbidities include 24 with current or recent IDU, alcohol dependence, psychotic depression or schizophrenia, or missing all medical appointments other than the HCV. Twenty-seven of 30 have completed their prescribed course of HCV therapy and 20 have achieved an SVR at 12 weeks. The 1 patient who failed was admitted to the hospital 4 times in the first 6 weeks of treatment and did not take his medication consistently. An additional 2 remain on treatment and 6 are awaiting results of testing done at 12 weeks post-therapy completion. One patient died within 2 weeks of initiating therapy due to a perforated duodenal ulcer.

Conclusion. Using targeted on-site HCV testing, we identified high prevalence sites. Implementing a simplified HCV treatment program reduces patient and clinic burden and resulted in 95% achieving SVR12 despite severe comorbidities. Expansion of this program to other clinics in Wake County is underway.

Disclosures. All Authors: No reported Disclosures.

2899. Decreased Hepatitis C Virus-Associated Mortality in the US 2014–2017 After New Oral Direct-Acting Antiviral Era
Zainab Wasti, MD; Dagan Coppock, MD; Edgar Chou, MD and Dong Heun Lee, MD; Drexel University College of Medicine, Philadelphia, Pennsylvania
Session: 310. Hepatitis C: Progress on Elimination and Treatment Saturday, October 5, 2019: 4:03 PM
Background. Due to the ease of use and low side effect profile of new direct-acting antivirals (DAAs), cure rates for hepatitis C virus (HCV) infection have increased.
in recent years. However, limited data exist addressing the mortality associated with HCV infection since the advent of DAAs. This study examines multiple-cause-of-death (MCOD) data from 2014 to 2017 to describe changes in HCV-associated mortality in the United States.

**Methods.** We examined death certificate information from public use MCOD data obtained from the National Center for Health Statistics. All-cause mortality associated with HCV, as defined by ICD-10 codes (B17.1 and B18.2), was evaluated. The age-adjusted crude mortality rate was calculated. Overall HCV-associated mortality, stratified by race and gender, was analyzed.

**Results.** From 2011 to 2017, the number of deaths associated with HCV, as listed in death certificates decreased from 19,613 to 17,253. This represents an average of 4% decrease in mortality each year. Crude age-adjusted mortality decreased from 5.01 (95% CI 4.93–5.08) deaths per 100,000 people in 2014 to 4.13 (95% CI 4.07–4.20) deaths per 100,000 people in 2017. Males had age-adjusted mortality of 6.82 (95% CI 6.76−6.88) and females had age-adjusted mortality of 2.59 (95% CI 2.55−2.63). African Americans had age-adjusted mortality of 7.50 (95% CI 7.37−7.63), and whites had age-adjusted mortality of 4.39 (95% CI 4.35−4.42) during the three-year period.

**Conclusion.** After the introduction of DAAs in 2014, mortality associated with HCV significantly decreased in the United States. There were differences in mortality rates by gender and race, which may reflect differences in HCV seroprevalence. With the availability of effective, well-tolerated HCV treatment, aggressive HCV screening and treatment programs are needed to reduce mortality associated with HCV.

**Disclosures. All Authors:** No reportedDisclosures.